[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-373085-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-373085-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advances-in-melanoma-and-skin-cancers-editorial","Advances in Melanoma and Skin Cancers - Editorial","","Cutaneous melanoma, a highly aggressive form of skin cancer, accounts for a small fraction of cases yet drives most cancer-related skin cancer deaths, reflecting the urgent need for effective therapies. Advances over the past decade have been propelled by immunotherapy, especially immune checkpoint inhibitors, which substantially improve survival through restored immune recognition. Despite durable benefits for many patients, others experience poor outcomes, making predictive biomarkers essential. This Special Issue highlights recent research on immunotherapy for skin cancers, including biomarker discovery and mechanistic studies such as multi-omics signatures and metabolic targeting in melanoma.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advances-in-melanoma-and-skin-cancers-editorial/373085/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advances-in-melanoma-and-skin-cancers-editorial/373085.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is cutaneous melanoma considered especially aggressive?","Question",{"text":63,"@type":64},"Although it represents about 4% of all skin cancers, it causes around 80% of skin cancer-related deaths, indicating high aggressiveness and an urgent therapeutic need.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role have immune checkpoint inhibitors played in advanced melanoma?",{"text":68,"@type":64},"Immune checkpoint inhibitors have shifted treatment paradigms by reactivating the immune system’s capacity to recognize and eliminate cancer cells, producing substantially improved survival and durable responses for many patients.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is identifying predictive biomarkers important?",{"text":72,"@type":64},"Some patients still have poor outcomes after immunotherapy. Predictive biomarkers can help prevent overtreatment, reduce toxicity risk, and avoid wasting resources.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},373085,1790838324,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":123},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Editorial  \nAdvances in Melanoma and Skin Cancers  \nDomenico Mallardo 1,*, Debora Basile 2 and Maria Grazia Vitale 1  \nReceived: 23 January 2025  \nRevised: 7 February 2025  \nAccepted: 18 February 2025  \nPublished: 21 February 2025  \nCitation: Mallardo, D.; Basile, D.; Vitale, M.G. Advances in Melanoma and Skin Cancers. Int. J. Mol. Sci. 2025, 26, 1849. [https://doi.org/10.3390/](https://doi.org/10.3390/)  \nijms26051849  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS“Fondazione G. Pascale”, Via Mariano Semmola, 53, 80131 Naples, Italy  \n2 Unit of Medical Oncology, Ospedale San Giovanni di Dio, 88900 Crotone, Italy  \n* Correspondence: [d.mallardo@istitutotumori.na.it](d.mallardo@istitutotumori.na.it); Tel.: +39-081-590-3111  \nCutaneous melanoma, with a continuously rising incidence worldwide, represents one of the most aggressive forms of skin cancer. Despite accounting for only 4% of all skin cancers, it is responsible for 80% of skin cancer-related deaths, highlighting its particular aggressiveness and the critical need for effective therapeutic strategies. The global burden of melanoma has increased significantly over the past decades, with current estimates suggesting that over 331,722 new cases are diagnosed annually worldwide [1,2] .  \nThis rising incidence, coupled with the complexity of treating advanced disease, has driven intensive research efforts in developing more effective therapeutic approaches. Recent epidemiological studies have shown significant variations in melanoma incidence across different geographical regions and populations, with the highest rates observed in Australia and New Zealand.  \nImmunotherapy has revolutionized the treatment landscape of advanced melanoma over the past decade, marking a paradigm shift in cancer treatment. The introduction of immune checkpoint inhibitors (ICIs) has represented a particularly significant breakthrough, offering substantially improved survival compared to previous therapies.  \nThis therapeutic revolution began with the understanding of how cancer cells evade immune surveillance and the subsequent development of strategies to reactivate the system’s natural ability to recognize and eliminate cancer cells.  \nThe success of ICIs in melanoma has not only transformed patient outcomes but also paved the way for immunotherapy applications in other cancer types. Long-term survival data from pivotal clinical trials demonstrate the unprecedented durability of responses, with some patients maintaining disease control for several years [3–5] .  \nHowever, a proportion of patients still experience poor outcomes after immunotherapy, as confirmed by several studies [6–10] . As a result, identifying predictive biomarkers of the response to immunotherapy is an important area of research, aiming to prevent overtreatment, unnecessary risk of toxicity, and wasteful resource usage. Since gene expression signatures in liquid biopsies are non-invasive and repeatable tests that may provide high specificity and sensitivity [11], they are widely investigated as potential predictive or prognostic markers in cancer patients, specifically in subjects with cutaneous melanoma [12–14] .  \nThe main goal of this Special Issue is to explore the most recent advancements in immunotherapy for patients with skin cancers. The studies included cover a wide range of research and treatment aspects, providing a comprehensive and in-depth view of the challenges and opportunities in this rapidly evolving field. This collection of studies provides a comprehensive and up-to-date overview of the main trends and future challenges ","cbCaimo0CTBldVfQ","https://ap.wps.com/l/cbCaimo0CTBldVfQ","pdf",158865,"English","# Editorial\n## Epidemiology and therapeutic need\n## Immunotherapy breakthroughs and limitations\n## Biomarkers and liquid biopsy gene signatures\n## Scope of the Special Issue\n## Selected research directions","[{\"question\":\"Why is cutaneous melanoma considered especially aggressive?\",\"answer\":\"Although it represents about 4% of all skin cancers, it causes around 80% of skin cancer-related deaths, indicating high aggressiveness and an urgent therapeutic need.\"},{\"question\":\"What role have immune checkpoint inhibitors played in advanced melanoma?\",\"answer\":\"Immune checkpoint inhibitors have shifted treatment paradigms by reactivating the immune system’s capacity to recognize and eliminate cancer cells, producing substantially improved survival and durable responses for many patients.\"},{\"question\":\"Why is identifying predictive biomarkers important?\",\"answer\":\"Some patients still have poor outcomes after immunotherapy. Predictive biomarkers can help prevent overtreatment, reduce toxicity risk, and avoid wasting resources.\"}]","Advances in Melanoma and Skin Cancers - Editorial | PDF",1790196712]